Transmedics

TMDX

Market cap $4.96B

TransMedics is helping improve organ transplantation thanks to its innovative organ storage system. The company has posted strong financial results over the past few years, and the stock is soaring.

ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025.

TransMedics posts 200% EPS surge and 32% revenue growth in Q4, tops estimates and guides for up to 25% sales growth in 2026.

TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

TransMedics (TMDX) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.19 per share a year ago.

ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2025.

Besides Wall Street's top-and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 18, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 40,089 shares of its common stock and an aggregate of 26,549 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.

ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.